Press Release

Global Critical Care Antiarrhythmic Drugs Market to Reach USD 1733.37 billion by 2032, Aided by the Regulatory Backing to Novel Drug Formulations

Global Critical Care Antiarrhythmic Drugs Market

According to a new report by EMR titled, ‘Global Critical Care Antiarrhythmic Drugs Market Report and Forecast 2024-2032’, the critical care antiarrhythmic drugs industry reached USD 1061.49 million in 2023. The market is expected to grow at a CAGR of 5.62% during 2024-2032 to reach a value of around USD 1733.37 million by 2032.

An increase in the prevalence of cardiovascular disorders in various parts of the world, along with an increase in the number of geriatric populations suffering from chronic diseases, are likely to enhance the antiarrhythmic drugs market over the forecast period. The COVID-19 pandemic has emphasised the need of maintaining heart health, as people with heart-related comorbidities are more likely to contract the coronavirus. As a result of the coronavirus, critical care anti-arrhythmogenic medications have become more widely used around the world. Rising FDA approvals of new antiarrhythmic drugs for treating atrial arrhythmias and a significant number of antiarrhythmic agents under development for several indications are projected to create new market opportunities.


Read more about this report - REQUEST FREE SAMPLE COPY IN PDF


Clinical trials and the development of novel drugs are being heavily pursued by a number of government-funded organisations, academic institutions, and private businesses, which are contributing to the market's growth. For example, ANI Pharmaceuticals (NASDAQ: ANIP) launched Mexiletine Hydrochloride Capsules USP in June 2020, marking the company's sixth generic pharmaceutical launch of the year. The capsules are recommended for the treatment of life-threatening ventricular arrhythmias.


Market Analysis by Drug Class, End-Use, and Regions:

  • Based on drug class, the market is divided into bovine, human, and recombinant, among others.
  • On the basis of end-use, the market is divided into hospitals and diagnostics, among others.


Key Findings of the Report:

  • Increasing research and development activities is estimated to boost the market growth.
  • Increased disease awareness is further augmenting the growth of the market.
  • The advanced health care infrastructure is further propelling the growth of the market.
  • Government intervention in curbing the number of deaths is further aiding in market growth.


Key Offerings of the Report:

  • The EMR report gives an overview of the global critical care antiarrhythmic drugs market for the periods (2018-2023) and (2024-2032).
  • The report also offers the historical (2018-2023) and forecasted (2024-2032) markets for drug class, end-use, and major regions of critical care antiarrhythmic drugs.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.


The major players in the global critical care antiarrhythmic drugs industry are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.


About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.


EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.


Contact Us:

Expert Market Research
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-579


*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.